Description
Evista is the trade name for Raloxifene, a second-generation selective estrogen receptor modulator (SERM) in the Benzothiophene family. in some tissues, while in others it acts as their agonist or activator.
The main difference between Evista and Tamoxifen is the selective effect on different tissue groups. Raloxifene is a potent antiestrogen in the breast and genitourinary tract, but acts as a pro-estrogenic agent in bone. Thus, its intake protects bone density, mimicking the positive effects of natural estradiol. Tamoxifen acts as an antiestrogen in both the breasts and the bones.
The US Food and Drug Administration (FDA) has approved the use of Evista for the treatment of osteoporosis and postmenopausal symptoms in women, and the drug has potential use in the prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, urinary cancer roads and acromegaly.
Bodybuilders use its antiestrogenic action to eliminate side effects when using flavoring steroids. The main goal is to eliminate gynecomastia, with which Raloxifene handles more than 2 times better than Tamoxifen (significant reduction of gynecomastia in 86% of cases compared to 41% with Nolvadex (Tamoxifen) at 3-9 months) and less harmful side effects.
In addition, at a daily dose of 120 mg. (2 tablets), Evista has been shown to increase serum and bioactive (free) testosterone by 20% even in men aged 60-70 years.
The drug has another plus because it has a partial estrogenic effect on serum lipids and reduces the levels of all types of cholesterol – total, good (HDL) and bad (LDL) cholesterol. This helps bodybuilders alleviate some of the negative health effects of steroids on the cardiovascular health.
Among the negative effects is the suppression of the production of insulin-like growth factor-1 (IGF-1) – when taking 120 mg. daily (2 times x 1 tablet of 60 mg.), serum IGF-1 levels decreased by an average of 16%.
In addition, estrogen has a positive effect on anabolic processes, as it increases the concentration of androgen receptors and increases the levels of enzymes involved in the processing of glucose used for tissue growth and regeneration. Therefore, it is considered that antiestrogens should not be used unless there is a specific and mandatory reason for this. Raloxifene is no exception in suppressing the pro-anabolic effects of estrogen and at higher doses, in addition to eliminating the excess estrogen side effects of the steroid cycle, can reduce to zero and its full anabolic potential.
The recommended dose for bodybuilders, which will effectively eliminate gynecomastia without other negative effects, is 60 mg. or 1 tablet daily. It is a better choice than first-generation drugs such as Nolvadex and Chlomida, as it is more gentle on the heart and cardiovascular system than other powerful aromatase inhibitors.
